Time spent in glycaemic control with sustained body weight reduction with tirzepatide: A post hoc analysis of the SURPASS clinical trial programme
EndocrinologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Diabetes, obesity & metabolism
- Publicado em
- 13 mar 2025
- Citações
- 6
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Time spent in glycaemic control with sustained body weight reduction with tirzepatide: A post hoc analysis of the SURPASS clinical trial programme
Brandon K Bergman, Julio Rosenstock, W Timothy Garvey, Rachel L Batterham, Yanyun Chen, Minzhi Liu, Palash Sharma, Chrisanthi A Karanikas, Vivian T Thieu
Descritores MeSH
- Glycemic Control
- Diabetes Mellitus, Type 2
- Hypoglycemic Agents
- Weight Loss
- Aged
- Blood Glucose
- Tirzepatide
- Drug Administration Schedule
- Adult
- Double-Blind Method
Veja também
Estudos relacionados
- Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg as an Add-On to Dose-Reduced Insulin Glargine versus Dose-Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE)
- Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial
- Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial
- Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial